SCAnIO: Cost-Effective Platform for Single-Cell Analysis in Immuno-Oncology
Objective:
Research in oncology is undergoing a revolution due to the rise of immuno-oncology treatments. The development of these treatments requires a detailed understanding of the targeted tissues, particularly the tumor and immune system, with a focus on their intrinsic heterogeneity. Access to this information is now possible with technologies that allow transcriptome analysis of the multitude of unique cells constituting a tissue. However, the implementation and use of these technologies are limited and expensive, reducing R&D throughput. Additionally, the complexity of data interpretation presents a barrier to their routine use.
Project Overview:
To address these challenges, AltraBio, Cellenion, and the Léon Bérard Center have joined forces to develop specific technologies and create a high-throughput platform for sorting and analyzing multi-parametric single cells in immuno-oncology. The goal of this project is to establish a methodological and optimized chain, ranging from tissue dissociation to data analysis, through optimized isolation and fluorescence sorting of cells at a reduced cost. The result will be a service platform dedicated to R&D issues in the field of immuno-oncology.
Duration:
- Project Duration: 4 years (12/2018 – 11/2022)
- Budget: 1.4M euros
- Grant: 750k euros
- Program Type: Programme d’Investissements d’Avenir (PIA3) de la région Auvergne Rhône-Alpes
Involved partners:
- Cellenion, Principal Investigator: Cellenion Website
- Centre Léon Bérard: Centre Léon Bérard Website (in French)
- AltraBio: AltraBio Website
